
## Karen Cravero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1105567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>NOTCH1</i> PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. Oncotarget, 2022, 13, 373-386.	0.8	1
2	Multisystem organ failure secondary to acute generalised exanthematous pustulosis (AGEP) with atypical presentation resembling septic shock. BMJ Case Reports, 2022, 15, e247040.	0.2	2
3	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. Journal of Clinical Investigation, 2021, 131, .	3.9	11
4	TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Research and Treatment, 2020, 179, 631-642.	1.1	10
5	Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 375-379.	2.3	2
6	The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. Breast Cancer Research and Treatment, 2019, 174, 401-412.	1.1	2
7	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. Journal of Clinical Investigation, 2019, 129, 4708-4723.	3.9	41
8	Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Practical Laboratory Medicine, 2018, 12, e00108.	0.6	3
9	PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Research and Treatment, 2017, 162, 451-464.	1.1	16
10	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. Clinical Cancer Research, 2017, 23, 4875-4884.	3.2	35
11	Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR. Clinical Chemistry, 2017, 63, 1370-1376.	1.5	6
12	The Impact of Collisions on the Ability to Detect Rare Mutant Alleles Using Barcode-Type Next-Generation Sequencing Techniques. Cancer Informatics, 2017, 16, 117693511771923.	0.9	1
13	Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, 2017, 8, 15651-15662.	0.8	20
14	A Polycythemia VeraJAK2Mutation Masquerading as a Duodenal Cancer Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1495-1498.	2.3	12
15	Circulating Tumor DNA—the Potential of Liquid Biopsies. Current Breast Cancer Reports, 2016, 8, 14-21.	0.5	2
16	<i>ESR1</i> Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 993-999.	3.2	152
17	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget, 2016, 7, 6281-6293.	0.8	76
18	A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct <i>PIK3CA</i> mutations. Proteomics, 2015, 15, 318-326.	1.3	13

2

KAREN CRAVERO

#	Article	IF	CITATIONS
19	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clinical Biochemistry, 2015, 48, 993-998.	0.8	91
20	<i>HER2</i> missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6205-14.	3.3	69
21	<i>NDRG1</i> links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11583-11588.	3.3	21
22	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget, 2015, 6, 25240-25251.	0.8	9
23	<i>MACROD2</i> overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17606-17611.	3.3	56
24	Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Human Pathology, 2014, 45, 1546-1550.	1.1	12